$763.25
0.57[0.07%]
At close: May 14
$763.25
0[0.00%]
PreMarket: 5:16PM EDT
Eli Lilly and Co
(NYSE:LLY)Latest News for Eli Lilly and Co Stock (NYSE:LLY)
Eli Lilly and Co Stock (NYSE: LLY)
Categories: All
Tuesday, May 14, 2024
- Eli Lilly Provides Update On Mounjaro And Zepbound Compounding Litigation; Enters Settlement Requiring Totality Medispa To Make Monetary Payment, Prohibiting Misleading Conduct, And Reporting Adverse Events To FDABenzinga Newsdesk - 11 hours ago
- 'Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs' - WSJBenzinga Newsdesk - 11 hours ago
- Argus Research Maintains Buy on Eli Lilly and Co, Raises Price Target to $840Benzinga Newsdesk - 16 hours ago
Monday, May 13, 2024
Thursday, May 09, 2024
Wednesday, May 08, 2024
Tuesday, May 07, 2024
- Hedge Fund Legend Druckenmiller Shares His Top Secrets For 30% ReturnsNatan Ponieman - May 7, 2024, 5:53PM
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - May 7, 2024, 1:35PM
- What About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next MonthVandana Singh - May 7, 2024, 12:38PM
- Eli Lilly Says FDA To Convene In-person Meeting Of Peripheral & Central Nervous System Drugs Advisory Committee On June 10, To Discuss DonanemabBenzinga Newsdesk - May 7, 2024, 9:41AM
Monday, May 06, 2024
- $100 Invested In This Stock 15 Years Ago Would Be Worth $2,200 TodayBenzinga Insights - May 6, 2024, 5:00PM
- Lilly shares are trading higher after the stock fell last week on competing weight loss drug updates from Amgen.Benzinga Newsdesk - May 6, 2024, 3:41PM
- This Is What Whales Are Betting On Eli Lilly and CoBenzinga Insights - May 6, 2024, 11:45AM
Friday, May 03, 2024
- Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc ClaimsZacks - May 3, 2024, 4:00PM
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - May 3, 2024, 1:35PM
- Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals IndustryBenzinga Insights - May 3, 2024, 11:00AM
- Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running UpThe Arora Report - May 3, 2024, 10:58AM
- Lilly and Novo Nordisk shares are trading lower following a weight loss drug update from Amgen.Benzinga Newsdesk - May 3, 2024, 8:20AM
Thursday, May 02, 2024
- Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and MounjaroVandana Singh - May 2, 2024, 4:01PM
- Unpacking the Latest Options Trading Trends in Eli Lilly and CoBenzinga Insights - May 2, 2024, 11:19AM
- Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly CompetitionBenzinga Neuro - May 2, 2024, 5:48AM
Wednesday, May 01, 2024
- Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'Vandana Singh - May 1, 2024, 3:26PM
- BMO Capital Maintains Outperform on Eli Lilly and Co, Raises Price Target to $1001Benzinga Newsdesk - May 1, 2024, 12:56PM
- JP Morgan Maintains Overweight on Eli Lilly and Co, Raises Price Target to $900Benzinga Newsdesk - May 1, 2024, 10:46AM
- Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With ExpectationsVandana Singh - May 1, 2024, 10:38AM
- Cantor Fitzgerald Maintains Overweight on Eli Lilly and Co, Raises Price Target to $885Benzinga Newsdesk - May 1, 2024, 10:15AM
- What 23 Analyst Ratings Have To Say About Eli Lilly and CoBenzinga Insights - May 1, 2024, 10:01AM
- Truist Securities Maintains Buy on Eli Lilly and Co, Raises Price Target to $892Benzinga Newsdesk - May 1, 2024, 8:42AM
Tuesday, April 30, 2024
- Eli Lilly's Outlook To Positive From Stable By Moody'sBenzinga Newsdesk - Apr 30, 2024, 4:41PM
- Americans Swap $5 Burgers For $1,000 Weight Loss Drugs — Is Soda Getting Left Behind Too?Aaron Bry - Apr 30, 2024, 3:22PM
- Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes DrugsVandana Singh - Apr 30, 2024, 3:11PM
- Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Raises Price Target to $885Benzinga Newsdesk - Apr 30, 2024, 1:46PM
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Apr 30, 2024, 1:35PM
- Stocks Dive On Fears Of Hawkish Fed; Treasury Yields Rise, Bitcoin Tumbles To $60,000: What's Driving Markets Tuesday?Piero Cingari - Apr 30, 2024, 1:35PM
- Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Apr 30, 2024, 1:24PM
- Eli Lilly Says Proposed U.S. BIOSECURE Act Would Affect Pharmaceutical Supply Chain Elements; Currently Do Not See It To Have Material Impact On BusinessBenzinga Newsdesk - Apr 30, 2024, 12:14PM
- FOMC Meeting Samsung Over Takes Apple, AI Demand Indication Ahead From AMD, Amazon And Super MicroThe Arora Report - Apr 30, 2024, 11:19AM
- Eli Lilly Exec Says Demand For Incretins Will Outpace Supply Through This Year, Potentially Next Year; Expect That The Supply And Demand Situation Will Remain Quite Tight In The Near Term As Well As The Midterm; Co Will Continue To Invest And Ramp Production Into Next Year; Co Is "Making The Right Investments And Progressing Rapidly" On Ramping ProductionBenzinga Newsdesk - Apr 30, 2024, 11:15AM
- Eli Lilly Increases FY24 Outlook, Joins Brinker International, Zebra Technologies, 3M And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Apr 30, 2024, 10:53AM
- Lilly Exec Says Approval Of Mounjaro Multi-Dose Kwikpen In Europe Came In Slightly Ahead Of Co's Expectation Gives Co Additional Confidence In Ability To LaunchBenzinga Newsdesk - Apr 30, 2024, 10:47AM
- Eli Lilly Exec Says Expect Acceleration And Revenue Growth Through H2 2024 As Supply Of Incretin Medicines Continue To Ramp; Co Is Making Investments To Expand Where It Can Ramp Up Capacity For Its Incretin Medicines; Expect To Get Obstructive Sleep Apnea For Zepbound Covered By CMS And Medicare At The Time Of LaunchBenzinga Newsdesk - Apr 30, 2024, 10:47AM
- Eli Lilly Exec Says Co Is Working Tirelessly To Ramp Supply Of Tirzepatide And Expect Meaningful Increases In Shipment Volumes In H2 2024; Co Remains On Track To Meet Expectations Set Earlier This Year For Production Of Incretin Medicines; Continues To Expects Production Of Salable Doses Of Incretin Medicine In H2 2024 To Be At Least 1.5x Saleable Doses In H2 2023Benzinga Newsdesk - Apr 30, 2024, 10:46AM
- Eli Lilly Exec Says Continue To Make Progress On Co's Plans To Increase Manufacturing Capacity; Wisconsin Facility Acquired From Nexus Pharma Has Been FDA Approved; Targeting To Initiate Production At 2025-End; Demand For Tirzepatide Continues To Outstrip Even With Increased SupplyBenzinga Newsdesk - Apr 30, 2024, 10:46AM
- Benzinga Opening Bell Update: Lilly Raises Guidance, Tesla Pulls Back, Treasury Yields RiseBenzinga Newsdesk - Apr 30, 2024, 10:23AM
- Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual ForecastVandana Singh - Apr 30, 2024, 9:41AM
- Wall Street On Edge Ahead Of Fed Decision, Spotlight Falls On Amazon And AMD Earnings: Analyst Says Stocks Survive 'Fragility Test' As April EndsShanthi Rexaline - Apr 30, 2024, 6:57AM
- Eli Lilly Expects 2024 Revenue Of $42.4B-$43.6B Versus Prior Guidance Of $40.4B-$41.6B And Consensus Of $41.36BBenzinga Newsdesk - Apr 30, 2024, 6:51AM
- Eli Lilly Revises 2024 Adjusted EPS Guidance To $13.50-$14.00 Versus Prior Guidance Of $12.20-$12.70 And Consensus Of $12.46.Benzinga Newsdesk - Apr 30, 2024, 6:50AM
- Eli Lilly shares are trading higher after the company raised its FY24 revenue guidance.Benzinga Newsdesk - Apr 30, 2024, 6:49AM